# Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Patients With Hospital-acquired Pneumonia

> **NCT03711331** · NA · COMPLETED · sponsor: **University Hospital, Lille** · enrollment: 161 (actual)

## Conditions studied

- Pneumonia, Ventilator-Associated
- Pneumonia, Bacterial

## Interventions

- **OTHER:** FilmArray® Pneumonia panel plus
- **OTHER:** Standard care

## Key facts

- **NCT ID:** NCT03711331
- **Lead sponsor:** University Hospital, Lille
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-16
- **Primary completion:** 2023-09-22
- **Final completion:** 2023-09-22
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2026-04-07

## Collaborators

- Curetis GmbH

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03711331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03711331, "Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Patients With Hospital-acquired Pneumonia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03711331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*